Fujian Akeylink Biotechnology Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Oct 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due May 7 to 14, 2027 · next May 7
- 1 fee due Jun 10, 2027The maintenance fee for Pyridone compound as c-met inhibitor (US 10,501,443) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
- 1 fee due Oct 9, 2027The maintenance fee for Crystal form of tri-cycle compound and application thereof (US 11,952,388) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Nov 10 US 12,790,317 Ring-Modified Proline Short Peptide Compound and Use Thereof
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,501,443 | Pyridone compound as c-met inhibitor In force · USPTO record | In force | USPTO record | |
| US 10,787,435 | ASK1 inhibitor and preparation method and use thereof In force · USPTO record | In force | USPTO record | |
| US 11,053,260 | Tri-Cycle Compound and Applications Thereof In force · High confidence | In force | High confidence | |
| US 11,040,968 | Pyridine derivative as ASK1 inhibitor and preparation method and use thereof In force · USPTO record | In force | USPTO record | |
| US 11,008,331 | Hepatitis B Virus Surface Antigen Inhibitor In force · High confidence | In force | High confidence | |
| US 11,465,986 | Crystal form of c-MET inhibitor and salt form thereof and preparation method therefor In force · USPTO record | In force | USPTO record | |
| US 11,814,382 | Crystal form as ASK1 inhibitor and preparation method and application thereof In force · USPTO record | In force | USPTO record | |
| US 11,807,647 | Crystal form of hepatitis B surface antigen inhibitor and application thereof In force · USPTO record | In force | USPTO record | |
| US 11,952,388 | Crystal form of tri-cycle compound and application thereof In force · USPTO record | In force | USPTO record | |
| US 12,103,936 | Crystal form of hepatitis B surface antigen inhibitor In force · USPTO record | In force | USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 2 no status recorded